Top

Published in:

01-02-2012 | Current Opinion

Possibility of a New Anti-Alzheimer’s Disease Pharmaceutical Composition Combining Memantine and Vitamin D

Authors: Cédric Annweiler, MD, PhD, Olivier Beauchet

Published in: Drugs & Aging | Issue 2/2012

Abstract

Alzheimer’s disease (AD) is the leading cause of dementia. In addition to a decrease in brain cholinergic activity, AD is also marked by glutamatergic excitotoxicity that results in neuronal death, characterized clinically by a loss of learning and memory abilities. The currently available drugs for symptomatic treatment of AD (i.e. memantine and acetylcholinesterase inhibitors) only temporarily slow down the natural history of the disease process. Among them, memantine is the only one that acts as a non-competitive low-affinity modulator of N-methyl-D-aspartate (NMDA) receptors. Memantine’s modulation of NMDA receptors has been reported to prevent the neuronal necrosis induced by glutamatergic calcium neurotoxicity, but not the neuronal apoptosis resulting from oxidative stress. This observation calls for new drug regimen strategies based on memantine combined with molecules having antioxidant effects, in order to create a multi-target therapy to increase neuronal protection and prevent AD progression. We wish to highlight that vitamin D is a secosteroid hormone that is suggested to have neuroprotective effects that include regulation of neuronal calcium homeostasis, as well as antioxidant, neurotrophic and anti-inflammatory properties. The combination of memantine plus vitamin D may provide, in one treatment, enhanced protection against several degenerative processes linked to AD. Based on the present rationale, a clinical trial testing this hypothesis is currently in recruitment (AD-IDEA trial; ClinicalTrials.gov identifier: NCT01409694). This new pharmaceutical composition may provide an effective solution to the problem of neuronal death and cognitive decline in AD.

Abbott A. Dementia: a problem for our age. Nature 2011; 475(7355): S2–4PubMedCrossRef

Ballard B, Gauthier S, Corbett A, et al. Alzheimer’s disease. Lancet 2011; 377(9770): 1019–31PubMedCrossRef

Querfurth HW, LaFerla FM. Alzheimer’s disease. N Engl J Med 2010; 362(4): 329–44PubMedCrossRef

Vellas B, Aisen PS. Early Alzheimer’s trials: new developments. J Nutr Health Aging 2010; 14(4): 293PubMedCrossRef

Aisen PS. Pre-dementia Alzheimer’s trials: overview. J Nutr Health Aging 2010; 14(4): 294PubMedCrossRef

Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev 2006; (1): CD005593

McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev 2006; (2): CD003154

Cavalli A, Bolognesi ML, Minarini A, et al. Multi-target-directed ligands to combat neurodegenerative diseases. J Med Chem 2008; 51(3): 347–72PubMedCrossRef

Ho R, Ortiz D, Shea TB. Amyloid-beta promotes calcium influx and neurodegeneration via stimulation of L voltage-sensitive calcium channels rather than NMDA channels in cultured neurons. J Alzheimers Dis 2011; 3(5): 479–83

10.

Ankarcrona M, Dypbukt JM, Bonfoco E, et al. Glutamate-induced neuronal death: a succession of necrosis or apoptosis depending on mitochondrial function. Neuron 1995; 15(4): 961–73PubMedCrossRef

11.

Bonfoco E, Krainc D, Ankarcrona M, et al. Apoptosis and necrosis: two distinct events induced, respectively, by mild and intense insults with N-methyl-D-aspartate or nitric oxide/superoxide in cortical cell cultures. Proc Natl Acad Sci U S A 1995; 92(16): 7162–6PubMedCrossRef

12.

Hardingham GE. Coupling of the NMDA receptor to neuroprotective and neurodestructive events. Biochem Soc Trans 2009; 37 (Pt 6): 1147–60PubMedCrossRef

13.

Pinheiro PS, Mulle C. Presynaptic glutamate receptors: physiological functions and mechanisms of action. Nat Rev Neurosci 2008; 9(6): 423–36PubMedCrossRef

14.

McEntee WJ, Crook TH. Glutamate: its role in learning, memory, and the aging brain. Psychopharmacology (Berl) 1993; 111(4): 391–401CrossRef

15.

Moult PR. Neuronal glutamate and GABAA receptor function in health and disease. Biochem Soc Trans 2009; 37 (Pt 6): 1317–22PubMedCrossRef

16.

Kauer JA, Malenka RC, Nicoll RA. NMDA application potentiates synaptic transmission in the hippocampus. Nature 1988; 334(6179): 250–2PubMedCrossRef

17.

Walton HS, Dodd PR. Glutamate-glutamine cycling in Alzheimer’s disease. Neurochem Int 2007; 50(7–8): 1052–66PubMedCrossRef

18.

Dong XX, Wang Y, Qin ZH. Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases. Acta Pharmacol Sin 2009; 30(4): 379–87PubMedCrossRef

19.

Gouras GK, Tampellini D, Takahashi RH, et al. Intraneuronal beta-amyloid accumulation and synapse pathology in Alzheimer’s disease. Acta Neuropathol 2010; 119(5): 523–41PubMedCrossRef

20.

Sokolow S, Luu SH, Vinters HV, et al. P1-240 — glutamatergic (VGLUT1) synapses are not lost in Alzheimer’s disease cerebral cortex, but preferentially accumulate amyloid-beta and p-tau pathology [abstract]. Alzheimers Dement 2010; 6: S243CrossRef

21.

Thibault O, Gant JC, Landfield PW. Expansion of the calcium hypothesis of brain aging and Alzheimer’s disease: minding the store. Aging Cell 2007; 6(3): 307–17PubMedCrossRef

22.

Hirsch EC. Does oxidative stress participate in nerve cell death in Parkinson’s disease? Eur Neurol 1993; 33Suppl. 1: 52–9PubMedCrossRef

23.

Olanow CW. A radical hypothesis for neurodegeneration. Trends Neurosci 1993; 16(11): 439–44PubMedCrossRef

24.

Francis PT. Glutamatergic systems in Alzheimer’s disease. Int J Geriatr Psychiatry 2003; 18Suppl. 1: S15–21PubMedCrossRef

25.

Meldrum B, Garthwaite J. Excitatory amino acid neurotoxicity and neurodegenerative disease. Trends Pharmacol Sci 1990; 11(9): 379–87PubMedCrossRef

26.

Portera-Cailliau C, Hedreen JC, Price DL, et al. Evidence for apoptotic cell death in Huntington disease and excitotoxic animal models. J Neurosci 1995; 15 (5 Pt 2): 3775–87PubMed

27.

Robinson DM, Keating GM. Memantine: a review of its use in Alzheimer’s disease. Drugs 2006; 66(11): 1515–34PubMedCrossRef

28.

Rogawski MA, Wenk GL. The neuropharmacological basis for the use of memantine in the treatment of Alzheimer’s disease. CNS Drug Rev 2003; 9(3): 275–308PubMedCrossRef

29.

Parsons CG, Stoffler A, Danysz W. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system: too little activation is bad, too much is even worse. Neuropharmacology 2007; 53(6): 699–723PubMedCrossRef

30.

Herrmann N, Li A, Lanctot K. Memantine in dementia: a review of the current evidence. Expert Opin Pharmacother 2011; 12(5): 787–800PubMedCrossRef

31.

Chen HS, Pellegrini JW, Aggarwal SK, et al. Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity. J Neurosci 1992; 12(11): 4427–36PubMed

32.

Lipton SA. Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat Rev Drug Discov 2006; 5(2): 160–70PubMedCrossRef

33.

Annweiler C, Souberbielle JC, Schott AM, et al. Vitamin D in the elderly: 5 points to remember. Geriatr Psychol Neuropsychiatr Vieil 2011; 9(3): 259–67PubMed

34.

Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357(3): 266–81PubMedCrossRef

35.

Annweiler C, Schott AM, Berrut G, et al. Vitamin D and ageing: neurological issues. Neuropsychobiology 2010; 62(3): 139–50PubMedCrossRef

36.

Kalueff AV, Tuohimaa P. Neurosteroid hormone vitamin D and its utility in clinical nutrition. Curr Opin Clin Nutr Metab Care 2007; 10(1): 12–9PubMedCrossRef

37.

Garcion E, Wion-Barbot N, Montero-Menei CN, et al. New clues about vitamin D functions in the nervous system. Trends Endocrinol Metab 2002; 13(3): 100–5PubMedCrossRef

38.

Dickens AP, Lang IA, Langa KM, et al. Vitamin D, cognitive dysfunction and dementia in older adults. CNS Drugs 2011; 25(8): 629–39PubMedCrossRef

39.

Holmøy T, Moen ST, Gundersen TA, et al. 25-Hydroxyvitamin D in cerebrospinal fluid during relapse and remission of multiple sclerosis. Mult Scler 2009; 15(11): 1280–5PubMedCrossRef

40.

Balabanova S, Richter HP, Antoniadis G, et al. 25-Hydroxyvitamin D, 24, 25-dihydroxyvitamin D and 1,25-dihydroxyvitamin D in human cerebrospinal fluid. 1984; 62(22): 1086–90

41.

Gezen-Ak D, Dursun E, Yilmaze S. The effects of vitamin D receptor silencing on the expression of LVSCC-A1C and LVSCC-AD1D and the release of NGF in cortical neurons. PLoS One 2011; 6(3): e17553PubMedCrossRef

42.

Eyles DW, Smith S, Kinobe R, et al. Distribution of the vitamin D receptor and 1 alphahydroxylase in human brain. J Chem Neuroanat 2005; 29(1): 21–30PubMedCrossRef

43.

Matsuda H. The role of neuroimaging in mild cognitive impairment. Neuropathology 2007; 27(6): 570–7PubMedCrossRef

44.

Price DL. Aging of the brain and dementia of the Alzheimer type. In: Kandel ER, Schwartz J, Jessel TM, editors. Principals of neural science. New York: McGraw-Hill, 2000: 1149–61

45.

Bouillon R, Carmeliet G, Verlinden L, et al. Vitamin D and human health: lessons from vitamin D receptor null mice. Endocr Rev 2008; 29(6): 726–76PubMedCrossRef

46.

Wang TT, Tavera-Mendoza LE, Laperriere D, et al. Large scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol 2005; 19(11): 2685–95PubMedCrossRef

47.

Lue LF, Kuo YM, Beach T, et al. Microglia activation and anti-inflammatory regulation in Alzheimer’s disease. Mol Neurobiol 2010; 41(2–3): 115–28PubMedCrossRef

48.

Brewer LD, Thibault V, Chen KC, et al. Vitamin D hormone confers neuroprotection in parallel with down-regulation of L-type calcium channel expression in hippocampal neurons. J Neurosci 2001; 21(1): 98–108PubMed

49.

Dursun E, Gezen-Ak D, Yilmaze S. A novel perspective for Alzheimer’s disease: vitamin D receptor suppression by amyloid-β induced alterations by vitamin D in cortical neurons. J Alzheimers Dis 2011; 23(2): 207–19PubMed

50.

Ibi M, Sawada H, Nakanishi M, et al. Protective effects of 1 alpha,25-(OH)(2)D(3) against the neurotoxicity of glutamate and reactive oxygen species in mesencephalic culture. Neuropharmacology 2001; 40(6): 761–71PubMedCrossRef

51.

Berridge MJ. Neuronal calcium signaling. Neuron 1998; 21(1): 13–26PubMedCrossRef

52.

Demaurex N, Distelhorst C. Cell biology. Apoptosis-the calcium connection. Science 2003; 300(5616): 65–7PubMedCrossRef

53.

Berridge MJ. Calcium signal transduction and cellular control mechanisms. Biochim Biophys Acta 2004; 1742(1–3): 3–7PubMedCrossRef

54.

Coon A, Wallace DR, Mactutus CF, et al. L-type calcium channels in the hippocampus and cerebellum. Neurobiol Aging 1999; 20(6): 597–603PubMedCrossRef

55.

Alexianu ME, Robbins E, Carswell S, et al. 1Alpha, 25 dihydroxyvitamin D3-dependent up-regulation of calcium-binding proteins in motoneuron cells. J Neurosci Res 1998; 51(1): 58–66PubMedCrossRef

56.

DeViragh PA, Haglid KG, Celio MR. Parvalbumin increases in the caudate putamen of rats with vitamin D hypervitaminosis. Proc Natl Acad Sci USA 1998; 86(10): 3887–90

57.

McCann JC, Ames BN. Is there convincing biological or behavioral evidence linking vitamin D deficiency to brain dysfunction? FASEB J 2008; 22(4): 982–1001PubMedCrossRef

58.

Wu CK, Thal L, Pizzo D, et al. Apoptotic signals within the basal forebrain cholinergic neurons in Alzheimer’s disease. Exp Neurol 2005; 195(2): 484–96PubMedCrossRef

59.

Palop JJ, Jones B, Kekonius L, et al. Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer’s disease-related cognitive deficits. Proc Natl Acad Sci USA 2003; 100(16): 9572–7PubMedCrossRef

60.

Dawson VL, Dawson TM. Nitric oxide actions in neurochemistry. Neurochem Int 1996; 29(2): 97–110PubMedCrossRef

61.

Garcion E, Nataf S, Berod A, et al. 1,25-Dihydroxyvitamin D3 inhibits the expression of inducible nitric oxide synthase in rat central nervous system during experimental allergic encephalomyelitis. Brain Res Mol Brain Res 1997; 45(2): 255–67PubMedCrossRef

62.

Garcion E, Sindji L, Montero-Menei C, et al. Expression of inducible nitric oxide synthase during rat brain inflammation: regulation by 1,25-dihydroxyvitamin D3. Glia 1998; 22(3): 282–94PubMedCrossRef

63.

Garcion E, Sindji L, Nataf S, et al. Treatment of experimental autoimmune encephalomyelitis in rat by 1,25-dihydroxyvitamin D3 leads to early effects within the central nervous system. Acta Neuropathol 2003; 105(5): 438–48PubMed

64.

Naveilhan P, Neveu I, Baudet C, et al. 1,25-dihydroxy vitamin D-3 regulates the expression of the low-affinity neurotrophin receptor. Mol Brain Res 1996; 41(1–2): 259–68PubMedCrossRef

65.

Neveu I, Naveilhan P, Jehan F, et al. 1,25-Dihydroxyvitamin D-3 regulates the synthesis of nerve growth-factor in primary cultures of glial-cells. Mol Brain Res 1994; 24(1–4): 70–6PubMedCrossRef

66.

Wion D, Macgrogan D, Neveu I, et al. 1,25-Dihydroxyvitamin-D3 is a potent inducer of nerve growth-factor synthesis. J Neurosci Res 1991; 28(1): 110–4PubMedCrossRef

67.

Brown J, Bianco JI, McGrath JJ, et al. 1,25-Dihydroxyvitamin D-3 induces nerve growth factor, promotes neurite outgrowth and inhibits mitosis in embryonic rat hippocampal neurons. Neurosci Lett 2003; 343(2): 139–43PubMedCrossRef

68.

Eyles D, Brown J, Mackay-Sim A, et al. Vitamin D-3 and brain development. Neurosci 2003; 118(3): 641–53CrossRef

69.

Ko P, Burkert R, McGrath J, et al. Maternal vitamin D(3) deprivation and the regulation of apoptosis and cell cycle during rat brain development. Brain Res Dev Brain Res 2004; 153(1): 61–8PubMedCrossRef

70.

Feron F, Burne TH, Brown J, et al. Developmental Vitamin D3 deficiency alters the adult rat brain. Brain Res Bull 2005; 65(2): 141–8PubMedCrossRef

71.

Tuszynski MH, Thal L, Pay M, et al. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med 2005; 11(5): 551–5PubMedCrossRef

72.

Wang Y, Chiang YH, Su TP, et al. Vitamin D(3) attenuates cortical infarction induced by middle cerebral arterial ligation in rats. Neuropharmacology 2000; 39(5): 873–80PubMedCrossRef

73.

Yu J, Gattoni-Celli M, Zhu H, et al. Vitamin D3-enriched diet correlates with a decrease of amyloid plaques in the brain of AbetaPP Transgenic Mice. J Alzheimers Dis 2011; 25(2): 295–307PubMed

74.

Sonnenberg J, Luine V-N, Krey L-C, et al. 1,25-dihydroxyvitamin D3 treatment results in increased choline acetyltransferase activity in specific brain nuclei. Endocrinology 1986; 118(4): 1433–9PubMedCrossRef

75.

Masoumi A, Goldenson B, Ghirmai S, et al. 1Alpha,25-dihydroxyvitamin D3 interacts with curcuminoids to stimulate amyloid-beta clearance by macrophages of Alzheimer’s disease patients. J Alzheimers Dis 2009; 17(3): 703–17PubMed

76.

Ito S, Ohtsuki S, Nezu Y, et al. 1α,25-Dihydroxyvitamin D3 enhances cerebral clearance of human amyloid-β peptide(1–40) from mouse brain across the blood-brain barrier [letter]. Fluids Barriers CNS 2011; 8: 20PubMedCrossRef

77.

Fantino B, Beauchet O, Savignat S, et al. Profile of French community-dwelling older adults supplemented with vitamin D: findings and lessons. Adv Ther 2011; 28(6): 483–9PubMedCrossRef

78.

Annweiler C, Allali G, Allain P, et al. Vitamin D and cognitive performance in adults: a systematic review. Eur J Neurol 2009; 16(10): 1083–9PubMedCrossRef

79.

Llewellyn DJ, Lang IA, Langa KM, et al. Vitamin D and risk of cognitive decline in elderly persons. Arch Intern Med 2010; 170(13): 1135–41PubMedCrossRef

80.

Annweiler C, Fantino B, Le Gall D, et al. Severe vitamin D deficiency is associated with advanced-stage dementia in geriatric inpatients. J Am Geriatr Soc 2011; 59(1): 169–71PubMedCrossRef

81.

Buell JS, Dawson-Hughes B, Scott TM, et al. 25-Hydroxyvitamin D, dementia, and cerebrovascular pathology in elders receiving home services. Neurology 2010; 74(1): 18–26PubMedCrossRef

82.

Oudshoorn C, Mattace-Raso FU, Van Der Velde N, et al. Higher serum vitamin D3 levels are associated with better cognitive test performance in patients with Alzheimer’s disease. Dementia Geriatr Cogn Disord 2008; 25(6): 539–43CrossRef

83.

Sato Y, Honda Y, Hayashida N, et al. Vitamin K deficiency and osteopenia in elderly women with Alzheimer’s disease. Arch Phys Med Rehabil 2005; 86(3): 576–81PubMedCrossRef

84.

Sato Y, Asoh T, Oizumi K. High prevalence of vitamin D deficiency and reduced bone mass in elderly women with Alzheimer’s disease. Bone 1998; 23(6): 555–7PubMedCrossRef

85.

Gezen-Ak D, Dursun E, Ertan T, et al. Association between vitamin D receptor gene polymorphism and Alzheimer’s disease. Tohoku J Exp Med 2007; 212(3): 275–82PubMedCrossRef

86.

Bouillon R, Carmeliet G, Daci E, et al. Vitamin D metabolism and action. Osteoporos Int 1998; 8Suppl. 2: S13–9PubMedCrossRef

87.

Beecham GW, Martin ER, Li YJ, et al. Genome-wide association study implicates a chromosome 12 risk locus for late-onset Alzheimer disease. Am J Hum Genet 2009; 84(1): 35–43PubMedCrossRef

88.

Annweiler C, Beauchet O. Vitamin D-mentia: randomized clinical trials should be the next step. Neuroepidemiology 2011; 37: 249–58PubMedCrossRef

89.

Annweiler C, Fantino B, Parot-Schinkel E, et al. Alzheimer’s Disease — Input of vitamin D with mEmantine Assay (AD-IDEA Trial): study protocol for a randomized controlled trial. Trials 2011; 12(1): 230PubMedCrossRef

90.

Annweiler C, Schott AM, Rolland Y, et al. Dietary intake of vitamin D and cognition in older women: a large population-based study. Neurology 2010; 75(20): 1810–6PubMedCrossRef

91.

University Hospital, Angers. Alzheimer’s Disease — Input of Vitamin D with mEmantine Assay (AD-IDEA) [ClinicalTrials.gov identifier NCT01409694]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 Dec 5]

92.

Nowson C. Vitamin D status of Australians: impact of changes to mandatory fortification of margarine with vitamin D. Canberra (ACT): Australia and New Zealand Food Authority, 2001

Title: Possibility of a New Anti-Alzheimer’s Disease Pharmaceutical Composition Combining Memantine and Vitamin D
Authors: Cédric Annweiler, MD, PhD
Olivier Beauchet
Publication date: 01-02-2012
Publisher: Springer International Publishing
Published in: Drugs & Aging / Issue 2/2012
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI: https://doi.org/10.2165/11597550-000000000-00000

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Possibility of a New Anti-Alzheimer’s Disease Pharmaceutical Composition Combining Memantine and Vitamin D

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2012

Potentially Inappropriate Prescribing in Older People with Dementia in Care Homes

RETRACTED ARTICLE: Three-year Experience with Alendronate Treatment in Postmenopausal Osteoporotic Japanese Women with or without Renal Dysfunction

Long-Term Safety, Tolerability and Efficacy of Fesoterodine in Subjects with Overactive Bladder Symptoms Stratified by Age

Drug-Induced Parkinsonism in the Elderly

Under-Prescribing and Non-Adherence to Medications after Coronary Bypass Surgery in Older Adults

Associations between Drug Burden Index and Mortality in Older People in Residential Aged Care Facilities

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page